Petauri PACT Executive Briefings - 3-Minute Market Insights
Welcome to the Petauri PACT Executive Briefing, where in 3-minutes we highlight healthcare’s critical market access issues, policies, challenges, or trends. This resource offers condensed, 3-minute episodes of market insights.
Our passion is on achieving the Quintuple Aim of enhancing patient experience, improving population health, reducing costs, improving the work life of health care providers and staff., and enhancing health equity in all aspects of care delivery.
I’m Dr. Warren Smedley, thank you for joining us.
Petauri PACT Executive Briefings - 3-Minute Market Insights
Introduction to Targeted Therapies: CAR T-cell Therapy
Introduction to Targeted Therapies: CAR T-cell Therapy
T-cell Transfer Therapy is a special type of immunotherapy that takes a person’s own T-cells (a type of immune cell), adds specific antigens to the T-cells that can identify the cancer cells, and puts them back into the person’s body. Cancer cells express unique antigens (signaling proteins). T-cells are programmed in the lab to find those signals and deliver a cancer stopping treatment right to the individual cancer cell. There are two main types of T-cell transfer therapy: tumor-infiltrating lymphocytes (TIL) and CAR T-cell Therapy.
Targeted therapies are evolving rapidly and are increasingly more patient specific, as well as significantly more complex to manufacture and deliver. With any of these therapies, life science companies may need to thoughtfully consider strategies for addressing market access needs, patient journey issues, and the complexities of clinical care delivery protocols.
Need more information? Please email us at Insights@thekinetixgroup.com
Check out @The Kinetix Group‘s growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics.